GlassScriptPhysician profile
Gregory John Ciliberti
NPI 1285657585
$419.01
in general payments reported to CMS, 2019-2025
12 companies · $31.34 in 2025
The $31.34 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.31 · 2020: $18.66 · 2021: $200 · 2022: $69.11 · 2023: $61.48 · 2024: $14.73 · 2025: $31.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $107.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $185.58 | 2021 | |
| Glaxosmithkline, LLC. | $35.10 | 2021-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $28.30 | 2023-2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $26.40 | 2022-2023 | |
| Qiagen, LLC | $23.71 | 2022 | |
| Vanda Pharmaceuticals INC. | $23.31 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.57 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $18.66 | 2020 | |
| Pfizer INC. | $16.56 | 2025 | |
| Exact Sciences Corporation | $14.78 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $14.09 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.95 | 2023 | Fasenra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Ciliberti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.